Publication | Closed Access

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

Breast OncologyOncologyLose RelianceMedicineBreast CancerCell BiologyCancer TreatmentCancer BiologyRadiation OncologyTumor Biology